ARO-Studien: Publikationen (Stand 23.08.2019)

 

Analkarzinom

  1. Grabenbauer GG, Panzer M, Hultenschmidt B, Doker R, Huber K, Kuhne-Velte HJ, Hutter M, Ruhl U, Budach V, Wendt T et al: [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients]. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 1994, 170(7):391-399.

 

Bronchialkarzinom

  1. Fleckenstein J, Hellwig D, Kremp S, Grgic A, Groschel A, Kirsch CM, Nestle U, Rube C: F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. International journal of radiation oncology, biology, physics 2011, 81(4):e283-289.
  2. Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, Kepka L, Marschke G, Feltl D, Fietkau R et al: Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011, 100(1):76-85.
  3. Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, Thames HD, Krause M, Baumann M: GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2013, 106(3):299-304.
  4. Eberhardt WE, Pottgen C, Gauler TC, Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W, Kimmich M et al: Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015, 33(35):4194-4201.
  5. Pottgen C, Gauler T, Bellendorf A, Guberina M, Bockisch A, Schwenzer N, Heinzelmann F, Cordes S, Schuler MH, Welter S et al: Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016, 34(21):2526-2533.
  6. Butof R, Simon M, Lock S, Troost EGC, Appold S, Krause M, Baumann M: PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial. Trials 2017, 18(1):608.
  7. Hechtner M, Krause M, Konig J, Appold S, Hornemann B, Singer S, Baumann M: Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2018, 126(2):283-290.
  8. Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K et al: Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. European journal of nuclear medicine and molecular imaging 2019, 46(7):1439-1447.

 

Glioblastom

  1. Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Gotz I, Schneider-Fuchs S, Weyerbrock A, Mader I, Baumert BG et al: Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC cancer 2016, 16(1):769.
  2. Straube C, Scherb H, Gempt J, Kirschke J, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE: Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial). BMC cancer 2018, 18(1):15.

 

Hodentumore

  1. Gobel U, Bamberg M, Calaminus G, Jurgens H, Pelzer V, Simon WE, Terruhn V, Wolf A, Mecke H, Harms D: [Dysgerminomas. Clinical aspects, therapy and prognosis with reference to the cooperative therapy study MAIKEI 83/86 for non-testicular germ cell tumors of the Society of Pediatric Oncology]. Geburtshilfe Frauenheilkd 1989, 49(8):737-742.
  2. Gobel U, Bamberg M, Haas RJ, Bokkerink JP, Bramswig G, Calaminus G, Engert J, Gadner H, Havers W, Janka-Schaub GE et al: [Non-testicular germ cell tumors: analysis of the therapy study MAKEI 83/86 anc changes in the protocol for the follow-up study]. Klin Padiatr 1989, 201(4):247-260.
  3. Gobel U, Bamberg M, Engert J, Gnekow AK, Haas HJ, Jurgens H, Kuhl J, Lenard HG, Lumenta C, Niethammer D et al: [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study]. Klin Padiatr 1991, 203(4):236-245.
  4. Gobel U, Calaminus G, Teske C, Bamberg M, Bokkerink JP, Haas RJ, Holschneider AM, Janka-Schaub G, Jurgens H, Mittler U et al: [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89]. Klin Padiatr 1993, 205(4):231-240.
  5. Schmidberger H, Bamberg M: [Treatment options in early-stage testicular seminoma. Review of the literature with initial results of a prospective multicenter study on radiotherapy of clinical-stage I, IIA and IIB seminomas]. Strahlenther Onkol 1995, 171(3):125-139.
  6. Schmidberger H, Bamberg M, Meisner C, Classen J, Winkler C, Hartmann M, Templin R, Wiegel T, Dornoff W, Ross D et al: Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997, 39(2):321-326.
  7. Bamberg M, Schmidberger H, Meisner C, Classen J, Souchon R, Weinknecht S, Schorcht J, Walter F, Engenhart-Cabillic R, Schulz U et al: Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer 1999, 83(6):823-827.
  8. Classen J, Souchon R, Hehr T, Bamberg M: Radiotherapy for early stages testicular seminoma: patterns of care study in Germany. Radiother Oncol 2002, 63(2):179-186.
  9. Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M, Loy V, German Testicular Cancer Study G: Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 2003, 88(6):828-831.
  10. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Kohrmann KU, Bamberg M: Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003, 21(6):1101-1106.
  11. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, Weissbach L, Budach V, Alberti W, Bamberg M et al: Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 2004, 90(12):2305-2311.
  12. Clasen J, Schmidberger H, Souchon R, Weissbach L, Hartmann M, Hartmann JT, Hehr T, Bamberg M: What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients. Strahlenther Onkol 2009, 185(6):349-354.

 

 

Kopf-Hals-Tumore

  1. Volling P, Staar S, Achterrath W, Muller RP: Phase I/II study of simultaneous carboplatin and radiotherapy in unresectable squamous cell carcinoma of the head and neck. Seminars in oncology 1992, 19(1 Suppl 2):66-71.
  2. Dinges S, Budach V, Stuschke M, Budach W, Boehmer D, Schrader M, Jahnke K, Sack H: Chemo-radiotherapy for locally advanced head and neck cancer--long-term results of a phase II trial. European journal of cancer 1997, 33(7):1152-1155.
  3. Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF, Bamberg M: Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial. International journal of radiation oncology, biology, physics 1997, 38(4):691-696.
  4. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998, 16(4):1318-1324.
  5. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000, 18(19):3339-3345.
  6. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. International journal of radiation oncology, biology, physics 2001, 50(5):1161-1171.
  7. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260.
  8. Ernst-Stecken A, Grabenbauer G, Iro H, Plasswilm L, Sauer R: Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2004, 180(12):805-810.
  9. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T et al: Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005, 23(6):1125-1135.
  10. Hehr T, Classen J, Belka C, Welz S, Schafer J, Koitschev A, Bamberg M, Budach W: Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. International journal of radiation oncology, biology, physics 2005, 61(5):1423-1431.
  11. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V: Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. International journal of radiation oncology, biology, physics 2005, 63(4):985-990.
  12. Kuhnt T, Becker A, Bloching M, Schubert J, Klautke G, Fietkau R, Dunst J: Phase II trial of a simultaneous radiochemotherapy with cisplatinum and paclitaxel in combination with hyperfractionated-accelerated radiotherapy in locally advanced head and neck tumors. Medical oncology 2006, 23(3):325-333.
  13. Semrau R, Mueller RP, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, Kocher M, Eich HT, Dietz A, Flentje M et al: Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. International journal of radiation oncology, biology, physics 2006, 64(5):1308-1316.
  14. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J: Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Annals of oncology : official journal of the European Society for Medical Oncology 2010, 21(11):2284-2289.
  15. Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG et al: Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 29(20):2815-2820.
  16. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M: Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012, 105(1):21-28.
  17. Budach V, Becker ET, Boehmer D, Badakhshi H, Jahn U, Wernecke KD, Stromberger C: Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2014, 190(3):250-255.
  18. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P: Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. International journal of radiation oncology, biology, physics 2015, 91(5):916-924.
  19. Ghadjar P, Pottgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F et al: Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94). Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2016, 192(8):552-560.
  20. Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Johrens K, Weichert W, Linge A, Lohaus F, Krause M et al: Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. European journal of cancer 2016, 57:78-86.
  21. Hess AK, Muer A, Mairinger FD, Weichert W, Stenzinger A, Hummel M, Budach V, Tinhofer I: MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. European journal of cancer 2017, 77:3-12.

 

Lymphome

  1. Hoederath A, Sack H, Stuschke M, Lampka E: [Radiotherapy of primary extranodal non-Hodgkin's lymphoma of the head and neck region. Results of a prospective multicenter study. Study Group NHL: early studies]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 1996, 172(7):356-366; discussion 367-358.
  2. Sack H, Hoederath A, Stuschke M, Bohndorf W, Makoski HB, Muller RP, Potter R: [Radiotherapy of follicle center lymphoma. Results of a German multicenter and prospective study. Members of the Study Group "NHL-early stages"]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 1998, 174(4):178-185; discussion 186.
  3. Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K: Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC cancer 2011, 11:87.

 

Mammakarzinom

  1. Winzer KJ, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, Schumacher M, German Breast Cancer Study G: Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. European journal of cancer 2010, 46(1):95-101.
  2. Dellas K, Vonthein R, Zimmer J, Dinges S, Boicev AD, Andreas P, Fischer D, Winkler C, Ziegler A, Dunst J et al: Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01). Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 2014, 190(7):646-653.

 

Metastasen

  1. Wiegel T, Bottke D, Kreusel KM, Schmidt S, Bornfeld N, Foerster MH, Hinkelbein W, German Cancer S: External beam radiotherapy of choroidal metastases--final results of a prospective study of the German Cancer Society (ARO 95-08). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002, 64(1):13-18.
  2. Rades D, Segedin B, Conde-Moreno AJ, Garcia R, Perpar A, Metz M, Badakhshi H, Schreiber A, Nitsche M, Hipp P et al: Radiotherapy With 4 Gy x 5 Versus 3 Gy x 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016, 34(6):597-602.

Pankreaskarzinom

  1. Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R: Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2003, 55(1):144-153.
  2. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG: Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008, 26(16):2699-2706.
  3. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T et al: Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 2015, 191(1):7-16.

 

Prostatakarzinom

  1. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M et al: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27(18):2924-2930.
  2. Bottke D, Golz R, Storkel S, Hinke A, Siegmann A, Hertle L, Miller K, Hinkelbein W, Wiegel T: Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. European urology 2013, 64(2):193-198.
  3. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A et al: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. European urology 2014, 66(2):243-250.
  4. Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stockle M, Rube C, Semjonow A, Wirth M, Storkel S et al: Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. International journal of radiation oncology, biology, physics 2015, 91(2):288-294.
  5. Habl G, Katayama S, Uhl M, Kessel KA, Edler L, Debus J, Herfarth K, Sterzing F: Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial. BMC cancer 2015, 15:868.
  6. Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C et al: Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial. Radiation oncology 2017, 12(1):138.

 

Rektumkarzinom

  1. Sauer R, Fietkau R, Wittekind C, Martus P, Rodel C, Hohenberger W, Jatzko G, Sabitzer H, Karstens JH, Becker H et al: Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 2001, 177(4):173-181.
  2. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21(16):3098-3104.
  3. Sauer R, Fietkau R, Wittekind C, Rodel C, Martus P, Hohenberger W, Tschmelitsch J, Sabitzer H, Karstens JH, Becker H et al: Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis 2003, 5(5):406-415.
  4. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(17):1731-1740.
  5. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005, 23(34):8688-8696.
  6. Fietkau R, Rodel C, Hohenberger W, Raab R, Hess C, Liersch T, Becker H, Wittekind C, Hutter M, Hager E et al: Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 2007, 67(4):1008-1019.
  7. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Furst A, Schwella N, Bieker M, Hellmich G et al: Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25(1):110-117.
  8. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S et al: Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008, 72(1):99-107.
  9. Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W et al: Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1081-1086.
  10. Kalata P, Martus P, Zettl H, Rodel C, Hohenberger W, Raab R, Becker H, Liersch T, Wittekind C, Sauer R et al: Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry. Dis Colon Rectum 2009, 52(3):425-437.
  11. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rodel C: Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010, 78(2):472-478.
  12. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR et al: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13(7):679-687.
  13. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30(16):1926-1933.
  14. Dellas K, Hohler T, Reese T, Wurschmidt F, Engel E, Rodel C, Wagner W, Richter M, Arnold D, Dunst J: Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013, 8:90.
  15. Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T, Dellas K, Kitz J, Rodel F, Sauer R et al: Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. Int J Radiat Oncol Biol Phys 2013, 87(5):992-999.
  16. Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohenberger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch J, Hess CF et al: Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol 2013, 108(1):48-54.
  17. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S et al: Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014, 32(15):1554-1562.
  18. Fokas E, Liersch T, Fietkau R, Hohenberger W, Hess C, Becker H, Sauer R, Wittekind C, Rodel C: Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon? Cancer 2015, 121(11):1724-1727.
  19. Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M et al: Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015, 16(8):979-989.
  20. Sprenger T, Rothe H, Conradi LC, Beissbarth T, Kauffels A, Kitz J, Homayounfar K, Wolff H, Strobel P, Ghadimi M et al: Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. Dis Colon Rectum 2016, 59(5):377-385.
  21. Fokas E, Strobel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, Hartmann A, Kaufmann M, Sauer R, Graeven U et al: Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. J Natl Cancer Inst 2017, 109(12).
  22. Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grutzmann R, Ghadimi M, Liersch T, Strobel P, Grabenbauer GG, Graeven U et al: Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol 2018, 29(7):1521-1527.
  23. Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, Fietkau R, Hohenberger W, Ghadimi M, Liersch T et al: Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Ann Oncol 2018, 29(8):1793-1799.
  24. Kitz J*, Fokas E*, Beissbarth T, Strobel P, Wittekind C, Hartmann A, Ruschoff J, Papadopoulos T, Rosler E, Ortloff-Kittredge P et al: Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial. JAMA Surg 2018, 153(8):e181607.
  25. Sprenger T, Beissbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR et al: Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94. Br J Surg 2018, 105(11):1510-1518.
  26. von den Grun JM, Hartmann A, Fietkau R, Ghadimi M, Liersch T, Hohenberger W, Weitz J, Sauer R, Wittekind C, Strobel P et al: Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. Radiother Oncol 2018, 128(3):557-563.
  27. Diefenhardt M, Hofheinz RD, Martin D, Beissbarth T, Arnold D, Hartmann A, von der Grun J, Grutzmann R, Liersch T, Strobel P et al: Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. Int J Cancer 2019.
  28. Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL et al: Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019:JCO1900308.

 

Zervixkarzinom

  1. Marnitz S, Martus P, Kohler C, Stromberger C, Asse E, Mallmann P, Schmidberger H, Affonso Junior RJ, Nunes JS, Sehouli J et al: Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. International journal of radiation oncology, biology, physics 2016, 94(2):243-253.